← Patent-cliff monitor small molecule NAYZILAM MIDAZOLAM
Loss of exclusivity January 2028 latest FDA-listed patent expiry
Company UCB → See this company's full patent-cliff portfolio Drug detail Brand name NAYZILAM Active ingredient MIDAZOLAM Strength 5MG/SPRAY Dosage form SPRAY Route NASAL Modality Small molecule FDA approval May 2019 Marketing status RX
Listed patents Patent Expires Type 9687495 January 2028 product 9289432 January 2028 product 8217033 January 2028 product 8809322 January 2028 product
Regulatory exclusivity Code Expires ODE-243 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.